FDA authorizes limited prescriptions of Paxlovid by pharmacists

Jul 06, 2022 - 04:05 PM
FDA-update-generic-drugs

The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization. 

Related News Articles

Headline
U.S. facility to help fill HHS monkeypox vaccine order
U.S.-based Grand River Aseptic Manufacturing will fill and finish 2.5 million of the 5.5 million vials of JYNNEOS monkeypox vaccine ordered by the Department…
Headline
HHS to allocate more vaccine, treatment for monkeypox next week
Jurisdictions that have used 90% of their JYNNEOS monkeypox vaccine supply and are administering the vaccine intradermally to adults can begin ordering…
Headline
States begin ordering more monkeypox vaccine
The Department of Health and Human Services Monday began accepting orders from states and other jurisdictions for a portion of 442,000 additional doses of the…
Headline
FDA does not recommend screening blood donors for monkeypox
The Food and Drug Administration Friday said it does not recommend screening or testing blood donors for the monkeypox virus, given “the robustness” of…
Headline
FDA recommends repeating COVID-19 at-home test in 48 hours if negative
The Food and Drug Administration yesterday advised people who get a negative result from an at-home COVID-19 antigen test to test themselves again after…
Headline
HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the…